Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Conflict of Interest TK has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly, and Novo Nordisk, for advisory boards from Novo Nordisk, and has participated in sponsored studies by Eli-Lilly and Novo Nordisk
Conclusion In conclusion, compared with placebo or other interventions, GLP-1 receptor agonists did not increase or decrease the risk of thyroid cancer, hyperthyroidism, hypothyroidism, thyroiditis, thyroid mass and goiter
Without-DAC means daily dosing and a more pulsatile, physiological GH response
declares additional funding for this work through the UK Medical Research Council (MRC) (MR/T033371/1), and NIHR Development and Skills Enhancement Award (NIHR301616)
doi: 10.3389/fimmu.2024.1420205 226 AbelAMYangCThakarMSMalarkannanS
US$ 25.19
US$ 22.00
US$ 20.82
US$ 22.32
US$ 22.38
